Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification.

Therapeutics

Health Care

Biotechnology

Orum Therapeutics

SJ Lee

Susan B.

Peter U. Park

Olaf Christensen

Greg Dwyer

The Scientific Research Team at Orum Therapeutics focuses on the development and optimization of Orum’s cell-penetrating antibody platform, Oromab™. This team is responsible for engineering antibodies that can penetrate cells to target cytosolic proteins, conducting medicinal chemistry and bioconjugation to enhance therapeutic efficacy, and advancing research to address unmet medical needs in cancer and rare diseases.

Scientific Research Team

Leadership Team

Operations Team

Scientific Research Team

About

Team members

Other teams at Orum Therapeutics

Leadership Team

Operations Team